該集團指,淨虧損減少主因VitaFlowLiberty經導管主動脈瓣膜及可回
收輸送系統已在海外20餘個國家╱地區銷售,海外收入增長兩倍以上、AnchorMan
左心耳封堵器系統及其導引系統在中國的商業化進展穩步推進,並於期內獲得CE標誌,並在歐
Please share this article if you like it!
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.